Hydron Technologies, Inc. Receives Formal US Patent Approval for its Method of Tissue Oxygenation

Name	Symbol	Market	Type
Robo Global Healthcare Technology and Innovation ETF	AMEX:HTEC	AMEX	Exchange Traded Fund

Name

Symbol

Market

Type

Robo Global Healthcare Technology and Innovation ETF

AMEX:HTEC

AMEX

Exchange Traded Fund

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.1318	0.45%	29.4134	29.3801	29.08	29.25	3,610	21:15:00

Price Change

% Change

Price

High Price

Low Price

Open Price

Traded

Last Trade

0.1318

0.45%

29.4134

29.3801

29.08

29.25

3,610

21:15:00

Hydron Technologies, Inc. Receives Formal US Patent Approval for its Method of Tissue Oxygenation

11/12/2003 4:11pm

PR Newswire (US)

Robo Global Healthcare T... (AMEX:HTEC)
Historical Stock Chart

From Jan 2020 to Jan 2025

Click Here for more Robo Global Healthcare T... Charts.

Hydron Technologies, Inc. Receives Formal US Patent Approval for its Method of Tissue Oxygenation POMPANO BEACH, Fla., Dec. 11 /PRNewswire-FirstCall/ -- Hydron Technologies, Inc. (BULLETIN BOARD: HTEC) announced today that the Company has received formal patent assignment, patent number 6,649,145, from the United States Patent and Trademark Office for its new tissue oxygenation technology. This technology has applications for improving current medical treatments and quality of life for burn victims, diabetics, wound care and post-surgical patients, and those suffering from pressure ulcers (bed sores). The patent could have a far reaching impact in these and other medical fields, as well as OTC and cosmeceutical skin care. Additional international patents for tissue oxygenation remain pending. The Company's super-oxygenation technology makes possible the delivery of pure oxygen through the skin to tissue depths considered therapeutic for wound healing and the maintenance of tissue viability. Hydron's technology utilizes microbubbles of pure oxygen, averaging one micron in diameter, to deliver oxygen deep into tissue. Using topical application, oxygen can now be targeted at specific problem areas and delivered into skin and tissue that is not receiving sufficient oxygen from the bloodstream, essentially oxygenating from the outside in. According to Terrence McGrath, Hydron Technologies' COO, "Tissue oxygen deprivation is common in a wide variety of medical conditions. Wounds typically have low blood supply from damaged capillaries, causing delayed healing and scaring. Infusing oxygen directly into the skin provides tissues with oxygen essential for cellular energy production and proper healing. Studies performed on healthy subjects at the University of Massachusetts Medical School demonstrated a significant increase in tissue oxygen levels beneath skin, and in one test achieving local tissue oxygen levels above those found in the arterial blood." McGrath finally added, "Hydron recently completed a private placement offering, raising $1.1 million, to accelerate its research and development program surrounding this technology." Hydron Technologies, Inc. markets a broad range of personal care products and is committed to the research and development of products and medical applications associated with its proprietary tissue oxygenation technology. The Company markets its skin care products through Hydron's direct-to-consumer catalog and on the Internet at http://www.hydron.com/. Catalogs are available by calling 1-800-4-HYDRON (1-800-449-3766). Except for historical information, all of the expectations and assumptions contained in the foregoing are forward-looking statements involving risks and uncertainties. For additional information regarding the risks associated with the Company's business, refer to Hydron Technologies, Inc. reports filed with the SEC. DATASOURCE: Hydron Technologies, Inc. CONTACT: Terrence S. McGrath, Chief Operating Officer, Hydron Technologies, Inc., +1-954-861-6416, or Web site: http://www.hydron.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

HTEC Robo Global Healthcare Technology and Innovation ETF